Page 16 - Human Data Science News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Despite COVID-19, pharma R&D funding at all-time high: IQVIA According to the clinical research solutions firm, disruptions due to the pandemic did not stop the industry from fueling R&D at unprecedented levels. The IQVIA Institute for Human Data Science has released its latest industry latest report, Global Trends in R&D: Overview Through 2020. According to the findings, research and development funding maintained historically high levels, thanks to new funding sources, strategic transactions, and other activity. Murray Aitken, executive director of the IQVIA Inst...

International Business News: SAS and strategic IoT partners simplify delivery of edge-to-cloud computing for customers - Mediawire

MM+M Podcast with Phreesia Life Sciences The COVID-19 pandemic has had a major impact on patients’ preferences and expectations when it comes to care, and it’s accelerated the move toward consumerism. Partner Content The key to estimating the actionable market share of your digital point-of-care media vendor: uncover what solutions they offer and who they can reach with those solutions. Partner Content, Podcasts MM+M Podcast with GCI Health The role of work-life balance in the agency world — especially in communications/PR ...

Photo: Thirdman/Pexels When the COVID-19 pandemic kicked off, everyone expected India to supply the bulk of the vaccines to poorer countries – in keeping with its image as ‘the pharmacy of the world’. India also appeared to accept this challenge quite willingly. However, the Indian government soon seemed to be treating the task of vaccinating almost 1.4 billion Indians like an elephant in the room. The dramatic turnaround in India’s approach that soon followed – from flaunting its credentials as ‘saviour’ of the world to ‘stopping exports’ against legal agreements – trigge...

Pharmaceutical companies that invested in coronavirus vaccine development will see big revenues. May 4th, 2021 It’s seldom that drug companies have the opportunity to develop a product that’s relevant to the entire world. In fact, it takes a global pandemic. IQVIA Institute for Human Data Science took on the task of estimating the financial impact of protecting the population from COVID-19, and the numbers are staggering. According to a recent FiercePharmaarticle that discussed the figures, global vaccine sales will reach $157B by 2025. This estimate accounts for dramatic drops in the co...